Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR0B1 | P51843 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.79 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.46 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.46 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SLC2A9 | Q9NRM0 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytochalasin D SCHEMBL33528 | 1.00 | NR0B1 (1.00) | NR0B1ADORA3CCR5MEN1KMT2A | |
| Cytochalasin D SCHEMBL16502284 | 1.00 | NR0B1 (1.00) | NR0B1ADORA3CCR5MEN1KMT2A | |
| Cytochalasin D SCHEMBL33529 | 1.00 | NR0B1 (1.00) | NR0B1ADORA3CCR5MEN1KMT2A | |
| Cytochalasin D SCHEMBL31734099 | 1.00 | NR0B1 (1.00) | NR0B1ADORA3CCR5MEN1KMT2A | |
| Cytochalasin D SCHEMBL25847004 | 1.00 | NR0B1 (1.00) | NR0B1ADORA3CCR5MEN1KMT2A | |
| Cytochalasin D SCHEMBL12648577 | 1.00 | NR0B1 (1.00) | NR0B1ADORA3CCR5MEN1KMT2A | |
| SCHEMBL29745878 | 0.93 | NR0B1 (0.86) | NR0B1ADORA3CCR5MEN1KMT2A | |
| Zygosporin D SCHEMBL34014 | 0.89 | NR0B1 (0.80) | NR0B1ADORA3CCR5MEN1KMT2A | |
| SCHEMBL22621306 | 0.88 | NR0B1 (0.79) | NR0B1ADORA3CCR5MEN1KMT2A | |
| SCHEMBL33708 | 0.88 | ADORA3 (1.00) | NR0B1ADORA3CCR5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3411059-B1 | METHOD TO ENHANCE THE EFFICIENCY OF SYSTEMIC AAV GENE DELIVERY TO THE CENTRAL NERVOUS SYSTEM | UNIV MASSACHUSETTS (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| EP-3734274-B1 | SYSTEM FOR MEASURING VISCOELASTIC PROPERTIES OF BLOOD | C A CASYSO GMBH (CH) | 2025-04-23 | — | — | EP | claimed |
| EP-4062962-B1 | BLOOD TESTING SYSTEM AND METHOD | C A CASYSO GMBH (CH) | 2023-10-04 | — | — | EP | claimed |
| EP-3140650-B1 | METHODOLOGIES AND REAGENTS FOR DETECTING FIBRINOLYSIS AND HYPERFIBRINOLYSIS | HAEMONETICS CORP (US) | 2022-07-20 | — | — | EP | claimed |
| US-20220125853-A1 | MATERIALS AND METHODS FOR ENHANCING BONE CELL DIFFERENTIATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-04-28 | — | — | US | claimed |
| EP-4308715-B1 | HYBRID MOLECULE COMPRISING AN ANTIBODY FC FRAGMENT AND AT LEAST ONE FIBRIN-DERIVED CITRULLINATED PEPTIDE, AND USES THEREOF | UNIV TOULOUSE 3 PAUL SABATIER (FR) | 2026-05-13 | — | — | EP | disclosed |
| US-20260102503-A1 | NANOCOMPOSITES FOR ENHANCED CELLULAR PAYLOAD DELIVERY | UNIV TEXAS (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260092102-A1 | COMPOSITIONS AND METHODS FOR USING BISPECIFIC ANTIBODIES TO BIND COMPLEMENT AND A TARGET ANTIGEN | REGENERON PHARMACEUTICALS, INC. | 2026-04-02 | — | — | US | disclosed |
| US-20260053804-A1 | Compositions and Methods for the Restoration of Ciliary Function | UNIV YALE (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4688821-A1 | MICROGLIAL ENDOCYTIC RECEPTORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASE | CERIMMUNE THERAPEUTICS AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-12539271-B2 | Nanoparticulate compositions | EMPA Eidgenössische Materialprüfungs-und Forschungsanstalt (CH) | 2026-02-03 | — | — | US | disclosed |
| CN-108780056-B | Dielectric sensing for sample characterization | 凯斯西储大学 | 2022-03-25 | — | — | CN | disclosed |
| WO-2022051592-A2 | METHODS AND MATERIALS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-03-10 | — | — | WO | disclosed |
| CN-114113572-A | Use of Piezo1 inhibitor for the manufacture of a medicament for the treatment or prevention of ectopic ossification | 中山大学附属第一医院 | 2022-03-01 | — | — | CN | disclosed |
| US-11254944-B2 | Agrobacterium derived cell penetrating peptides as nanocarriers | INDIAN INSTITUTE OF TECHNOLOGY DELHI (IN) | 2022-02-22 | — | — | US | disclosed |
| US-20220047719-A1 | ENHANCING SUBCUTANEOUS INJECTION AND TARGET TISSUE ACCUMULATION OF NANOPARTICLES VIA CO-ADMINISTRATION WITH MACROPINOCYTOSIS INHIBITORY NANOPARTICLES (MINP) | NORTHWESTERN UNIVERSITY | 2022-02-17 | — | — | US | disclosed |
| EP-3947467-A1 | METHODS OF DEPLETING DISEASE CAUSING AGENTS VIA ANTIBODY TARGETED PHAGOCYTOSIS | Dren Bio, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20220025331-A1 | METHODS AND SYSTEMS FOR IMPROVING CELLS FOR USE IN THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092102-A1 | COMPOSITIONS AND METHODS FOR USING BISPECIFIC ANTIBODIES TO BIND COMPLEMENT AND A TARGET ANTIGEN | FCGR3B, FCGR2A, C1QBP | NR0B1 1105/4885ADORA3 3157/4885CCR5 116/4885 |
| US-12539271-B2 | Nanoparticulate compositions | CA7, CA1, CA13 | NR0B1 3473/4885ADORA3 4713/4885CCR5 3501/4885 |
| US-20260053804-A1 | Compositions and Methods for the Restoration of Ciliary Function | MTCL3, DYNLL2, CEP170 | NR0B1 3871/4885ADORA3 3808/4885CCR5 4336/4885 |
| US-20260102503-A1 | NANOCOMPOSITES FOR ENHANCED CELLULAR PAYLOAD DELIVERY | TNNT2, TELO2, MAPT | NR0B1 3648/4885ADORA3 4468/4885CCR5 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.